The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1467
Umeclidinium (Incruse Ellipta) for COPD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Incruse Ellipta (GSK), a single-agent inhaler containing the long-acting anticholinergic umeclidinium, for once-daily maintenance treatment of chronic obstructive pulmonary disease (COPD). Umeclidinium was initially approved in combination with the long-acting beta2-adrenergic agonist vilanterol as Anoro Ellipta.1

MAINTENANCE TREATMENT — In patients with moderate to severe COPD, regular treatment with an inhaled long-acting bronchodilator (a beta2-agonist or an anticholinergic) can relieve symptoms, improve lung function, and reduce the frequency of exacerbations. A combination of a beta2-agonist and an anticholinergic can be used for patients inadequately controlled on a single agent.2

CLINICAL STUDIES — In a 12-week, double-blind trial, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Umeclidinium (Incruse Ellipta) for COPD
Article code: 1467c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian